<DOC>
	<DOCNO>NCT00464113</DOCNO>
	<brief_summary>The purpose study determine safe dose BCR-ABL inhibitor XL228 , often take , well people leukemia tolerate XL228 .</brief_summary>
	<brief_title>Study XL228 Subjects With Chronic Myeloid Leukemia Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<criteria>1 . The subject confirm pathologic diagnosis evidence presence BCRAbl translocation [ ( 9 ; 22 ) ] fluorescence situ hybridization ( FISH ) , cytogenetics , quantitative polymerase chain reaction ( QPCR ) one following : 1 . CML Chronic phase ( CP ) Accelerated phase ( AP ) Blast phase ( BP ) OR 2 . Ph+ ALL 2 . The subject one following : Known T315I Abl mutation Known resistance intolerance imatinib dasatinib At least one prior antileukemia therapy , include , limited , interferon , imatinib , dasatinib 3 . The subject least 18 year old . 4 . The subject Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 . 5 . The subject adequate organ function . 6 . The subject capable understanding comply protocol sign informed consent document . 7 . Sexually active subject must use accepted method contraception course study . 8 . Female subject childbearing potential must negative pregnancy test enrollment . 1 . The subject receive interferon , imatinib , dasatinib within 7 day first dose XL228 . 2 . The subject receive investigational agent radiotherapy within 28 day first dose XL228 . 3 . The subject receive immunosuppressive therapy ( eg , cyclosporine , steroid , tacrolimus graftversushost disease [ GVHD ] ) within 28 day prior first dose XL228 . 4 . The subject recover National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) v3.0 Grade ≤1 toxicity related peripheral stem cell bone marrow transplant . 5 . The subject recover CTCAE v3.0 Grade ≤1 adverse event ( AEs ) due investigational drug medication . 6 . The subject know allergy hypersensitivity component investigational drug product . 7 . The subject uncontrolled intercurrent illness include , limited , ongoing active infection , diabetes , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 8 . The subject pregnant breastfeeding . 9 . The subject know positive human immunodeficiency virus ( HIV ) . 10 . The subject inability unwillingness abide study protocol cooperate fully investigator designee .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Myeloid Leukemia</keyword>
	<keyword>Lymphocytic Leukemia</keyword>
	<keyword>Ph+ ALL</keyword>
</DOC>